MX2022013270A - Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido. - Google Patents

Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido.

Info

Publication number
MX2022013270A
MX2022013270A MX2022013270A MX2022013270A MX2022013270A MX 2022013270 A MX2022013270 A MX 2022013270A MX 2022013270 A MX2022013270 A MX 2022013270A MX 2022013270 A MX2022013270 A MX 2022013270A MX 2022013270 A MX2022013270 A MX 2022013270A
Authority
MX
Mexico
Prior art keywords
nucleoside analog
virus
viruses
present
formulation containing
Prior art date
Application number
MX2022013270A
Other languages
English (en)
Inventor
Yang He
Hualiang Jiang
Yuanchao Xie
Gengfu Xiao
Leike Zhang
Haji Akber Aisa
Jingshan Shen
Original Assignee
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica Cas filed Critical Shanghai Inst Materia Medica Cas
Publication of MX2022013270A publication Critical patent/MX2022013270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una aplicación antiviral de análogos de nucleósidos. Específicamente, la presente invención se relaciona con los usos de análogos de nucleósidos y una composición farmacéutica de los mismos como: (a) inhibidores para inhibir la replicación de coronavirus, virus de la influenza, virus sincitial respiratorio, virus flaviviridae, virus filoviridae y/o virus de la diarrea epidémica porcina (PEDV).); y/o (b) medicamentos para tratar y/o prevenir y mitigar enfermedades causadas por infecciones por coronavirus, virus de la influenza, virus respiratorio sincitial, virus flaviviridae, virus filoviridae y/o virus de la diarrea epidémica porcina (PEDV). Los análogos de nucleósidos de acuerdo con la invención pueden tratar y/o prevenir y mitigar la infección respiratoria, neumonía (COVID-19) y otras enfermedades relacionadas causadas por la infección por el nuevo coronavirus de 2019.
MX2022013270A 2020-04-20 2021-04-16 Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido. MX2022013270A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010313870 2020-04-20
CN202010568329 2020-06-19
CN202011035065.1A CN112778310A (zh) 2020-04-20 2020-09-27 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
PCT/CN2021/087928 WO2021213288A1 (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Publications (1)

Publication Number Publication Date
MX2022013270A true MX2022013270A (es) 2023-01-05

Family

ID=75750428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013270A MX2022013270A (es) 2020-04-20 2021-04-16 Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido.

Country Status (12)

Country Link
US (2) US11919923B2 (es)
EP (1) EP4141007A1 (es)
JP (1) JP2023526179A (es)
KR (1) KR20220143919A (es)
CN (3) CN112778310A (es)
AU (1) AU2021260618B2 (es)
BR (1) BR112022021226A2 (es)
CA (1) CA3171091A1 (es)
CO (1) CO2022015415A2 (es)
IL (1) IL297410A (es)
MX (1) MX2022013270A (es)
WO (1) WO2021213288A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
CN115362004A (zh) 2020-04-06 2022-11-18 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202233204A (zh) * 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
WO2022089302A1 (zh) * 2020-10-26 2022-05-05 苏州旺山旺水生物医药有限公司 一种核苷类似物的盐及其晶型、药物组合物和用途
CN114391016B (zh) * 2020-10-26 2023-06-30 苏州旺山旺水生物医药有限公司 一种核苷类似物的盐及其晶型、药物组合物和用途
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
CN114765979A (zh) * 2021-04-23 2022-07-19 苏州旺山旺水生物医药有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
CN113185519A (zh) * 2021-04-23 2021-07-30 苏州富德兆丰生化科技有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
CN113698405B (zh) * 2021-06-03 2022-09-27 南方科技大学坪山生物医药研究院 一种核苷类化合物的晶型及其制备方法
EP4355755A1 (en) 2021-06-14 2024-04-24 Venatorx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
PE20240654A1 (es) 2021-08-20 2024-04-04 Shionogi & Co Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral
CN117209555A (zh) * 2021-09-30 2023-12-12 中国科学院上海药物研究所 一类氰基化合物、其制备方法及用途
CN113999237B (zh) * 2021-10-29 2023-08-08 润佳（苏州）医药科技有限公司 一种核苷类前药及其用途
CA3237234A1 (en) * 2021-11-04 2023-05-11 Shenzhen Antiv Pharma Co., Ltd. Crystal form of isobutyrate nucleoside compound, and preparation method
CN116262110A (zh) * 2021-12-13 2023-06-16 苏州旺山旺水生物医药有限公司 口服氘代核苷或其可药用盐的药物组合物及制备方法和应用
CN117886872A (zh) * 2021-12-15 2024-04-16 南京知和医药科技有限公司 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途
CN114790210B (zh) * 2021-12-23 2023-06-27 深圳安泰维生物医药有限公司 一种核苷类化合物盐的晶型
CN114181258B (zh) * 2021-12-29 2023-10-13 南京师范大学 用于抗病毒治疗的核苷类化合物及用途
CN114605419A (zh) * 2021-12-30 2022-06-10 威科检测集团有限公司 一种具有抗新冠病毒活性的吡咯烷类化合物及其在药物中的应用
CN114516875B (zh) * 2022-01-26 2023-07-21 苏州旺山旺水生物医药有限公司 一种核苷类似物vv116的制备方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023167938A1 (en) * 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023168254A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN118021821A (zh) * 2022-03-03 2024-05-14 苏州旺山旺水生物医药股份有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途
CN114573590B (zh) * 2022-03-18 2023-11-14 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
WO2023186026A1 (zh) * 2022-03-31 2023-10-05 苏州旺山旺水生物医药有限公司 一种单异丁酰基核苷类似物的制备方法
WO2023196458A1 (en) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
CN114644651A (zh) * 2022-04-13 2022-06-21 中国人民解放军军事科学院军事医学研究院 芳氧基磷酰化氨基酸酯化合物的制备方法
CN114869893B (zh) * 2022-04-15 2023-09-15 苏州旺山旺水生物医药有限公司 一种药物组合物及其应用
CN116947947A (zh) * 2022-04-20 2023-10-27 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
US20230338409A1 (en) * 2022-04-25 2023-10-26 Miracure Biotechnology Limited Nucleoside drugs for the treatment or prevention of coronavirus infection and their uses
CN114917233B (zh) * 2022-05-05 2023-09-19 苏州旺山旺水生物医药有限公司 一种包含核苷类似物的药物组合物及其制备方法和应用
CA3227999A1 (en) * 2022-05-17 2023-11-23 Medshine Discovery Inc. Deuterated nucleoside compounds and use thereof
CN116850192A (zh) * 2022-05-27 2023-10-10 深圳安泰维生物医药有限公司 一种核苷类衍生化合物的药物组合物及其制备方法和用途
US20240009220A1 (en) 2022-06-06 2024-01-11 Gilead Sciences, Inc. Methods for treatment of viral infections
CN114796177B (zh) * 2022-06-27 2022-09-30 广州国家实验室 抗冠状病毒药物和应用
WO2024002112A1 (zh) * 2022-06-28 2024-01-04 苏州旺山旺水生物医药股份有限公司 一种治疗猫冠状或杯状病毒感染的方法
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
CN117503776A (zh) * 2022-08-05 2024-02-06 临港国家实验室 一种药物组合物及其用途
WO2024054618A1 (en) 2022-09-09 2024-03-14 Gilead Sciences, Inc. Methods for treatment of viral infections
WO2024088184A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anti-feline-coronavirus compounds and uses thereof
WO2024088183A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof
WO2024091624A1 (en) 2022-10-27 2024-05-02 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116217621B (zh) * 2023-04-26 2023-08-11 北京沐华生物科技有限责任公司 一种核苷类双前药、合成方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2268642E (pt) * 2008-04-23 2015-06-02 Gilead Sciences Inc Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral
CA2773773C (en) * 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI698444B (zh) * 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
EP3334745B1 (en) 2015-08-13 2024-05-15 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
PT3785717T (pt) * 2015-09-16 2022-04-14 Gilead Sciences Inc Métodos para o tratamento de infeções por coronaviridae
AR111490A1 (es) 2017-05-01 2019-07-17 Gilead Sciences Inc Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)
EP3684782A1 (en) * 2017-09-18 2020-07-29 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748944B (zh) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN110330540A (zh) 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 核苷盐及其制备方法
CN113248508A (zh) 2020-02-13 2021-08-13 安徽诺全药业有限公司 N-保护的杂环类化合物、其制备方法及其用于制备c-核苷衍生物的方法
CN111135184A (zh) * 2020-03-05 2020-05-12 华中农业大学 GS-441524在制备新型冠状病毒SARS-CoV-2抑制剂中的应用
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111620909B (zh) * 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用

Also Published As

Publication number Publication date
CN114096543B (zh) 2022-08-16
US11919923B2 (en) 2024-03-05
BR112022021226A2 (pt) 2022-12-06
KR20220143919A (ko) 2022-10-25
CN112778310A (zh) 2021-05-11
AU2021260618B2 (en) 2024-05-02
CN114096543A (zh) 2022-02-25
WO2021213288A1 (zh) 2021-10-28
EP4141007A1 (en) 2023-03-01
IL297410A (en) 2022-12-01
CN112778310A8 (zh) 2021-07-30
AU2021260618A1 (en) 2022-10-06
CO2022015415A2 (es) 2023-02-27
US20230219993A1 (en) 2023-07-13
CN115448924A (zh) 2022-12-09
AU2021260618A8 (en) 2022-10-27
CA3171091A1 (en) 2021-10-28
US20240140975A1 (en) 2024-05-02
JP2023526179A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
MX2022013270A (es) Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido.
MX2021013679A (es) Compuestos antivirales que contienen nitrilo.
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
BR112019000796A2 (pt) compostos e métodos para tratamento e prevenção da infecção flavivirus
BRPI0511283A (pt) aril aciltiouréias substituìdas e compostos relacionados; inibidores da replicação viral
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
MX2009012299A (es) Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue.
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
UY28084A1 (es) Derivados antivirales de nucleosidos
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2022217154A3 (en) Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
MX2022011173A (es) Tratamiento de infeccion por coronavirus.
BR112023002573A2 (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral
BR112023025358A2 (pt) Inibidores de protease como antivirais
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
WO2022065970A3 (ko) 천연물 혼합 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물
WO2022129097A3 (en) Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus